Drug Trial Radar · NCT00002798
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Last checked: Nov 20, 2026Latest source record: Jan 16, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
880
Actual
Start
Aug 1996
Primary completion
Sep 2006
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Randomized phase III trial to compare the effectiveness of different chemotherapy regimens with or without bone marrow transplantation in treating children who have acute myelogenous leukemia or myelodysplastic syndrome. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known which treatment regimen is more effective for acute myelogenous leukemia or myelodysplastic syndrome
Conditions
- Childhood Acute Erythroleukemia (M6)
- Childhood Acute Megakaryocytic Leukemia (M7)
- Childhood Acute Monoblastic Leukemia (M5a)
- Childhood Acute Monocytic Leukemia (M5b)
- Childhood Acute Myeloblastic Leukemia With Maturation (M2)
- Childhood Acute Myeloblastic Leukemia Without Maturation (M1)
- Childhood Acute Myelomonocytic Leukemia (M4)
- Childhood Myelodysplastic Syndromes
- Chronic Myelomonocytic Leukemia
- de Novo Myelodysplastic Syndromes
- Refractory Anemia
- Refractory Anemia With Excess Blasts
- Refractory Anemia With Excess Blasts in Transformation
- Refractory Anemia With Ringed Sideroblasts
- Secondary Myelodysplastic Syndromes
- Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions
asparaginaseDrug
daunorubicin hydrochlorideDrug
fludarabine phosphateDrug
therapeutic hydrocortisoneDrug
allogeneic bone marrow transplantationProcedure
3-dimensional conformal radiation therapyRadiation
filgrastimBiological
Given SC
cytarabineDrug
Given IV or IT
idarubicinDrug
Given IV
dexamethasoneDrug
Given PO
thioguanineDrug
Given PO
etoposideDrug
Given IV
methotrexateDrug
Given IT
cyclophosphamideDrug
Given IV
aldesleukinBiological
busulfanDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportions of patients achieving remission rate during induction therapyTime frame: Up to 42 days
- Proportion of patients dying or with residual disease during induction therapyTime frame: Up to 42 days
- Time to marrow recovery (induction phase)Time frame: Up to 42 days
- Frequency of toxicities, including infectious complications (induction phase)Time frame: Up to 42 days
- Marrow statusTime frame: At 14 days
- Percent of blastsTime frame: At the end of induction therapy
- Complete remission at the end of consolidation therapyTime frame: Up to 5 years
- Survival following consolidationTime frame: Up to 5 years
- Event-free survival following consolidationTime frame: Up to 5 years
- Overall survival (intensification)Time frame: Up to 5 years
- EFS (intensification)Time frame: Up to 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Children's Oncology Group
Arcadia, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.